Om Prakash Ganda, M.B.,B.S., M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypertriglyceridemia | 3 | 2023 | 293 | 1.540 |
Why?
|
| Diabetic Angiopathies | 11 | 2018 | 818 | 1.220 |
Why?
|
| Diabetes Mellitus | 30 | 2020 | 5751 | 1.180 |
Why?
|
| Hypercholesterolemia | 6 | 2015 | 1151 | 1.140 |
Why?
|
| Cholesterol | 15 | 2023 | 2917 | 1.000 |
Why?
|
| Diabetes Mellitus, Type 2 | 21 | 2023 | 11725 | 0.880 |
Why?
|
| Practice Guidelines as Topic | 6 | 2020 | 7279 | 0.880 |
Why?
|
| Dyslipidemias | 4 | 2018 | 849 | 0.840 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 6 | 2018 | 3255 | 0.830 |
Why?
|
| Hypolipidemic Agents | 6 | 2018 | 604 | 0.780 |
Why?
|
| Apolipoproteins B | 2 | 2012 | 374 | 0.670 |
Why?
|
| Atherosclerosis | 6 | 2023 | 3445 | 0.660 |
Why?
|
| Triglycerides | 13 | 2023 | 2454 | 0.650 |
Why?
|
| Hypoglycemic Agents | 5 | 2018 | 2872 | 0.600 |
Why?
|
| Cardiovascular Diseases | 10 | 2023 | 15165 | 0.530 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2018 | 841 | 0.480 |
Why?
|
| Diabetes Mellitus, Type 1 | 21 | 2012 | 3336 | 0.470 |
Why?
|
| Lipids | 11 | 2018 | 3305 | 0.430 |
Why?
|
| Blood Glucose | 22 | 2016 | 6256 | 0.430 |
Why?
|
| Cholesterol, LDL | 6 | 2023 | 2356 | 0.430 |
Why?
|
| Lipoproteins | 2 | 2023 | 878 | 0.390 |
Why?
|
| Lipid Metabolism | 2 | 2018 | 1889 | 0.350 |
Why?
|
| Fasting | 1 | 2016 | 1593 | 0.350 |
Why?
|
| Drug Prescriptions | 1 | 2018 | 1637 | 0.330 |
Why?
|
| Insulin | 23 | 2016 | 6580 | 0.330 |
Why?
|
| Sodium Chloride, Dietary | 1 | 2010 | 281 | 0.320 |
Why?
|
| Bile Acids and Salts | 1 | 2010 | 367 | 0.320 |
Why?
|
| Niacin | 2 | 2006 | 116 | 0.310 |
Why?
|
| Self Care | 7 | 2018 | 786 | 0.310 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2018 | 9959 | 0.290 |
Why?
|
| Hyperglycemia | 1 | 2016 | 1373 | 0.290 |
Why?
|
| Anticholesteremic Agents | 3 | 2010 | 979 | 0.280 |
Why?
|
| Nutritional Physiological Phenomena | 1 | 2007 | 370 | 0.260 |
Why?
|
| Hypertension | 5 | 2016 | 8480 | 0.250 |
Why?
|
| Insulin Resistance | 5 | 2012 | 3864 | 0.240 |
Why?
|
| Diabetes Complications | 5 | 2018 | 1359 | 0.210 |
Why?
|
| Comprehensive Health Care | 2 | 2015 | 127 | 0.210 |
Why?
|
| Islets of Langerhans | 14 | 1989 | 1352 | 0.190 |
Why?
|
| Antibodies, Monoclonal | 1 | 2018 | 9274 | 0.190 |
Why?
|
| Prediabetic State | 7 | 2018 | 499 | 0.190 |
Why?
|
| Diabetes Mellitus, Lipoatrophic | 1 | 2000 | 9 | 0.190 |
Why?
|
| Chromans | 1 | 2000 | 122 | 0.180 |
Why?
|
| Lipodystrophy | 1 | 2000 | 147 | 0.170 |
Why?
|
| Humans | 92 | 2023 | 744343 | 0.170 |
Why?
|
| Psychotherapy, Group | 2 | 2013 | 406 | 0.160 |
Why?
|
| Adiposity | 1 | 2007 | 1807 | 0.150 |
Why?
|
| Public Health | 1 | 2010 | 2603 | 0.150 |
Why?
|
| Fibrinogen | 2 | 1992 | 894 | 0.150 |
Why?
|
| Thiazolidinediones | 1 | 2000 | 476 | 0.150 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2020 | 582 | 0.140 |
Why?
|
| Diseases in Twins | 9 | 1986 | 449 | 0.140 |
Why?
|
| Diet Therapy | 1 | 2016 | 154 | 0.130 |
Why?
|
| Patient Compliance | 3 | 2015 | 2684 | 0.130 |
Why?
|
| Somatostatin | 4 | 1983 | 459 | 0.120 |
Why?
|
| India | 3 | 2016 | 2197 | 0.120 |
Why?
|
| Nutrition Policy | 1 | 2018 | 488 | 0.120 |
Why?
|
| Thiazoles | 1 | 2000 | 1483 | 0.110 |
Why?
|
| Health Behavior | 2 | 2016 | 2636 | 0.110 |
Why?
|
| Obesity | 5 | 2018 | 12745 | 0.110 |
Why?
|
| Basement Membrane | 3 | 1983 | 356 | 0.100 |
Why?
|
| Adult | 45 | 2018 | 214055 | 0.100 |
Why?
|
| Guidelines as Topic | 1 | 2018 | 1405 | 0.100 |
Why?
|
| Phosphatidylcholine-Sterol O-Acyltransferase | 1 | 2011 | 31 | 0.100 |
Why?
|
| Allylamine | 1 | 2010 | 10 | 0.100 |
Why?
|
| Middle Aged | 40 | 2018 | 213383 | 0.090 |
Why?
|
| Patient-Centered Care | 1 | 2020 | 1439 | 0.090 |
Why?
|
| Gastrointestinal Hormones | 2 | 1981 | 97 | 0.090 |
Why?
|
| Patient Education as Topic | 2 | 2013 | 2278 | 0.090 |
Why?
|
| Risk Reduction Behavior | 1 | 2016 | 1125 | 0.090 |
Why?
|
| Clinical Trials as Topic | 2 | 2018 | 7913 | 0.080 |
Why?
|
| Twins, Monozygotic | 7 | 1986 | 458 | 0.080 |
Why?
|
| Diabetes, Gestational | 1 | 2018 | 1184 | 0.080 |
Why?
|
| Hyperlipidemias | 3 | 2002 | 789 | 0.080 |
Why?
|
| Male | 47 | 2018 | 350118 | 0.080 |
Why?
|
| United States | 11 | 2018 | 69872 | 0.080 |
Why?
|
| Blood Sedimentation | 1 | 1988 | 231 | 0.080 |
Why?
|
| Lipoproteins, HDL | 4 | 2011 | 638 | 0.080 |
Why?
|
| Mannose | 2 | 1979 | 124 | 0.080 |
Why?
|
| Glucose Tolerance Test | 9 | 1986 | 1150 | 0.080 |
Why?
|
| Glucagon | 10 | 1986 | 533 | 0.080 |
Why?
|
| Female | 48 | 2018 | 380194 | 0.080 |
Why?
|
| Consensus | 1 | 2016 | 2959 | 0.070 |
Why?
|
| Disease Management | 1 | 2018 | 2459 | 0.070 |
Why?
|
| Adenoma, Islet Cell | 3 | 1987 | 82 | 0.070 |
Why?
|
| Overweight | 1 | 2018 | 2371 | 0.070 |
Why?
|
| Albuminuria | 1 | 1991 | 682 | 0.070 |
Why?
|
| Sex Distribution | 1 | 2012 | 2297 | 0.070 |
Why?
|
| Homozygote | 1 | 2011 | 1785 | 0.070 |
Why?
|
| Muscles | 3 | 1983 | 1614 | 0.070 |
Why?
|
| Aged | 22 | 2020 | 163280 | 0.070 |
Why?
|
| Gemfibrozil | 1 | 2005 | 30 | 0.070 |
Why?
|
| Aged, 80 and over | 6 | 2020 | 57776 | 0.070 |
Why?
|
| Risk Factors | 9 | 2016 | 72290 | 0.060 |
Why?
|
| Nutrition Surveys | 1 | 2012 | 1660 | 0.060 |
Why?
|
| Diabetic Nephropathies | 2 | 1992 | 984 | 0.060 |
Why?
|
| Amidines | 1 | 1984 | 30 | 0.060 |
Why?
|
| Treatment Outcome | 7 | 2018 | 63114 | 0.060 |
Why?
|
| Pentamidine | 1 | 1984 | 45 | 0.060 |
Why?
|
| Emigration and Immigration | 1 | 2007 | 404 | 0.060 |
Why?
|
| Valine | 1 | 2006 | 413 | 0.060 |
Why?
|
| Health Promotion | 1 | 2016 | 2205 | 0.060 |
Why?
|
| Cholesterol, HDL | 6 | 2009 | 1814 | 0.060 |
Why?
|
| Tolbutamide | 3 | 1984 | 23 | 0.060 |
Why?
|
| Glucose | 6 | 1984 | 4397 | 0.060 |
Why?
|
| Gastric Inhibitory Polypeptide | 2 | 1981 | 59 | 0.060 |
Why?
|
| Heptanoic Acids | 1 | 2005 | 343 | 0.060 |
Why?
|
| Risk Assessment | 3 | 2015 | 23338 | 0.060 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2006 | 451 | 0.050 |
Why?
|
| Autoantibodies | 7 | 1989 | 2035 | 0.050 |
Why?
|
| Simvastatin | 1 | 2005 | 360 | 0.050 |
Why?
|
| Capillaries | 2 | 1983 | 773 | 0.050 |
Why?
|
| Triplets | 2 | 1983 | 43 | 0.050 |
Why?
|
| Mutation, Missense | 1 | 2011 | 2564 | 0.050 |
Why?
|
| Aging | 1 | 2020 | 8664 | 0.050 |
Why?
|
| Endorphins | 1 | 1981 | 75 | 0.050 |
Why?
|
| Neurotensin | 1 | 1981 | 61 | 0.050 |
Why?
|
| Tetrazoles | 1 | 2006 | 835 | 0.050 |
Why?
|
| Exercise | 1 | 2016 | 5615 | 0.040 |
Why?
|
| Arteriosclerosis | 2 | 2000 | 1092 | 0.040 |
Why?
|
| Diet, Fat-Restricted | 2 | 2012 | 320 | 0.040 |
Why?
|
| Japan | 1 | 2003 | 1360 | 0.040 |
Why?
|
| Telemedicine | 1 | 2016 | 2872 | 0.040 |
Why?
|
| Twins | 1 | 1980 | 339 | 0.040 |
Why?
|
| Societies, Medical | 1 | 2011 | 3743 | 0.040 |
Why?
|
| Carotid Arteries | 1 | 2003 | 952 | 0.040 |
Why?
|
| Physician-Patient Relations | 1 | 2012 | 3229 | 0.040 |
Why?
|
| Growth Hormone | 2 | 1978 | 705 | 0.040 |
Why?
|
| Pyrroles | 1 | 2005 | 1146 | 0.040 |
Why?
|
| Prevalence | 3 | 2016 | 15226 | 0.040 |
Why?
|
| Galactose | 1 | 1979 | 306 | 0.040 |
Why?
|
| Hormones, Ectopic | 1 | 1977 | 40 | 0.040 |
Why?
|
| Fructose | 1 | 1979 | 288 | 0.040 |
Why?
|
| China | 1 | 2003 | 2248 | 0.040 |
Why?
|
| Environment | 1 | 2003 | 1124 | 0.040 |
Why?
|
| Preconception Care | 1 | 2018 | 134 | 0.040 |
Why?
|
| Methylglycosides | 1 | 1976 | 10 | 0.040 |
Why?
|
| Deoxy Sugars | 1 | 1976 | 20 | 0.040 |
Why?
|
| Methylglucosides | 1 | 1976 | 36 | 0.040 |
Why?
|
| Hypoglycemia | 1 | 1984 | 861 | 0.040 |
Why?
|
| Cost Savings | 2 | 2012 | 926 | 0.040 |
Why?
|
| Hormones | 2 | 1980 | 889 | 0.030 |
Why?
|
| Streptozocin | 1 | 1976 | 196 | 0.030 |
Why?
|
| Life Style | 1 | 2007 | 3835 | 0.030 |
Why?
|
| Amino Acids | 3 | 1976 | 1736 | 0.030 |
Why?
|
| Drug Monitoring | 2 | 2012 | 956 | 0.030 |
Why?
|
| Deoxyglucose | 1 | 1976 | 337 | 0.030 |
Why?
|
| Pancreatic Neoplasms | 4 | 1987 | 5256 | 0.030 |
Why?
|
| Nitrogen | 1 | 1976 | 344 | 0.030 |
Why?
|
| Rheumatoid Nodule | 1 | 1974 | 15 | 0.030 |
Why?
|
| Coronary Disease | 2 | 2003 | 6077 | 0.030 |
Why?
|
| Syndrome | 1 | 2000 | 3251 | 0.030 |
Why?
|
| Rheumatoid Factor | 1 | 1974 | 188 | 0.030 |
Why?
|
| Pravastatin | 1 | 1995 | 395 | 0.030 |
Why?
|
| Adolescent | 17 | 2012 | 85781 | 0.030 |
Why?
|
| Patient Care Planning | 1 | 2018 | 921 | 0.030 |
Why?
|
| Skin | 1 | 2006 | 4364 | 0.030 |
Why?
|
| Busulfan | 1 | 1973 | 263 | 0.030 |
Why?
|
| Reference Values | 2 | 2006 | 4982 | 0.030 |
Why?
|
| Proteinuria | 2 | 2011 | 658 | 0.030 |
Why?
|
| Arginine | 2 | 1986 | 944 | 0.030 |
Why?
|
| Ethanol | 1 | 1978 | 1342 | 0.030 |
Why?
|
| Motor Activity | 2 | 2012 | 2714 | 0.030 |
Why?
|
| Educational Status | 2 | 2012 | 2540 | 0.020 |
Why?
|
| Corneal Opacity | 1 | 2011 | 60 | 0.020 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2011 | 279 | 0.020 |
Why?
|
| Bone Marrow Diseases | 1 | 1973 | 231 | 0.020 |
Why?
|
| Fatty Acids, Nonesterified | 2 | 1978 | 402 | 0.020 |
Why?
|
| Body Composition | 1 | 2000 | 2401 | 0.020 |
Why?
|
| Fruit | 1 | 2016 | 1142 | 0.020 |
Why?
|
| Risk-Taking | 1 | 2016 | 986 | 0.020 |
Why?
|
| Vegetables | 1 | 2016 | 1182 | 0.020 |
Why?
|
| Geriatric Assessment | 1 | 2018 | 1372 | 0.020 |
Why?
|
| Alcoholism | 2 | 1978 | 1906 | 0.020 |
Why?
|
| Nephrectomy | 1 | 1976 | 1050 | 0.020 |
Why?
|
| Apolipoprotein A-I | 1 | 2011 | 281 | 0.020 |
Why?
|
| Smoking Cessation | 2 | 2012 | 2071 | 0.020 |
Why?
|
| Adrenal Medulla | 1 | 1989 | 58 | 0.020 |
Why?
|
| Pregnancy | 9 | 2018 | 29144 | 0.020 |
Why?
|
| Combined Modality Therapy | 2 | 2012 | 8642 | 0.020 |
Why?
|
| Animals | 3 | 2020 | 168757 | 0.020 |
Why?
|
| Adaptation, Psychological | 2 | 2012 | 2576 | 0.020 |
Why?
|
| Health Care Costs | 2 | 2012 | 3209 | 0.020 |
Why?
|
| Dietary Fats | 1 | 2016 | 2017 | 0.020 |
Why?
|
| Child | 14 | 2012 | 77709 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2011 | 1682 | 0.020 |
Why?
|
| Pyruvates | 3 | 1976 | 87 | 0.020 |
Why?
|
| Liver Diseases | 1 | 1976 | 1253 | 0.020 |
Why?
|
| Rheumatic Diseases | 1 | 1974 | 592 | 0.020 |
Why?
|
| Antigens | 4 | 1977 | 1466 | 0.020 |
Why?
|
| Injections, Intravenous | 3 | 1984 | 1420 | 0.020 |
Why?
|
| Radioimmunoassay | 3 | 1987 | 919 | 0.020 |
Why?
|
| Physical Fitness | 1 | 2011 | 733 | 0.020 |
Why?
|
| Lactates | 3 | 1976 | 432 | 0.020 |
Why?
|
| Renal Dialysis | 1 | 1976 | 1786 | 0.020 |
Why?
|
| Quality of Life | 3 | 2013 | 12804 | 0.020 |
Why?
|
| Administration, Oral | 3 | 2006 | 3913 | 0.020 |
Why?
|
| alpha-Fetoproteins | 1 | 1987 | 224 | 0.020 |
Why?
|
| Motivation | 1 | 2016 | 1971 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2016 | 5078 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2006 | 10943 | 0.020 |
Why?
|
| Body Constitution | 1 | 1986 | 278 | 0.020 |
Why?
|
| Homocysteine | 1 | 2009 | 647 | 0.020 |
Why?
|
| Waist Circumference | 1 | 2009 | 917 | 0.020 |
Why?
|
| HLA Antigens | 2 | 1983 | 1381 | 0.020 |
Why?
|
| Sex Factors | 3 | 2009 | 10397 | 0.020 |
Why?
|
| Somatostatinoma | 1 | 1983 | 10 | 0.020 |
Why?
|
| C-Reactive Protein | 2 | 2009 | 3778 | 0.020 |
Why?
|
| Double-Blind Method | 3 | 2006 | 12026 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 1992 | 6365 | 0.010 |
Why?
|
| Alanine | 2 | 1976 | 572 | 0.010 |
Why?
|
| Regional Blood Flow | 1 | 2006 | 1525 | 0.010 |
Why?
|
| Depression | 2 | 2012 | 7766 | 0.010 |
Why?
|
| Young Adult | 3 | 2016 | 56430 | 0.010 |
Why?
|
| Follow-Up Studies | 3 | 2013 | 39050 | 0.010 |
Why?
|
| Blood Pressure | 3 | 2006 | 8554 | 0.010 |
Why?
|
| Insulin Infusion Systems | 1 | 1983 | 212 | 0.010 |
Why?
|
| Pancreatic Polypeptide | 1 | 1981 | 34 | 0.010 |
Why?
|
| Forearm | 2 | 1976 | 409 | 0.010 |
Why?
|
| Peer Group | 1 | 2006 | 635 | 0.010 |
Why?
|
| Microcirculation | 1 | 2006 | 1286 | 0.010 |
Why?
|
| Cholecystokinin | 1 | 1981 | 114 | 0.010 |
Why?
|
| Enkephalins | 1 | 1981 | 154 | 0.010 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 1985 | 1475 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 2006 | 1641 | 0.010 |
Why?
|
| Cross-Over Studies | 1 | 2006 | 2029 | 0.010 |
Why?
|
| Probability | 1 | 2006 | 2505 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2011 | 4803 | 0.010 |
Why?
|
| Prostaglandins | 1 | 1980 | 405 | 0.010 |
Why?
|
| Fibrinolysis | 1 | 1980 | 322 | 0.010 |
Why?
|
| Prospective Studies | 4 | 2016 | 53288 | 0.010 |
Why?
|
| Interleukin-2 | 1 | 1986 | 1904 | 0.010 |
Why?
|
| Endpoint Determination | 1 | 2002 | 601 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2011 | 13815 | 0.010 |
Why?
|
| Thyroid (USP) | 1 | 1978 | 3 | 0.010 |
Why?
|
| Thyrotropin-Releasing Hormone | 1 | 1978 | 147 | 0.010 |
Why?
|
| Depression, Chemical | 1 | 1978 | 191 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 1992 | 12245 | 0.010 |
Why?
|
| Paraneoplastic Endocrine Syndromes | 1 | 1977 | 31 | 0.010 |
Why?
|
| Communication | 1 | 2012 | 3749 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2006 | 4933 | 0.010 |
Why?
|
| Portacaval Shunt, Surgical | 1 | 1977 | 49 | 0.010 |
Why?
|
| Physical Exertion | 1 | 1980 | 695 | 0.010 |
Why?
|
| Anxiety | 1 | 2012 | 4297 | 0.010 |
Why?
|
| Infusions, Parenteral | 1 | 1977 | 419 | 0.010 |
Why?
|
| Cortisone | 1 | 1977 | 89 | 0.010 |
Why?
|
| Mannoheptulose | 1 | 1976 | 1 | 0.010 |
Why?
|
| Alloxan | 1 | 1976 | 13 | 0.010 |
Why?
|
| Personality | 1 | 1980 | 552 | 0.010 |
Why?
|
| Social Conditions | 1 | 1977 | 126 | 0.010 |
Why?
|
| Propranolol | 1 | 1978 | 502 | 0.010 |
Why?
|
| Time Factors | 7 | 1984 | 40075 | 0.010 |
Why?
|
| Thyroid Hormones | 1 | 1978 | 390 | 0.010 |
Why?
|
| Histocompatibility Antigens | 1 | 1977 | 471 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1978 | 1681 | 0.010 |
Why?
|
| Ammonia | 1 | 1976 | 239 | 0.010 |
Why?
|
| Hepatic Encephalopathy | 1 | 1976 | 139 | 0.010 |
Why?
|
| Risk | 3 | 1985 | 9687 | 0.010 |
Why?
|
| Liver Cirrhosis | 2 | 1976 | 1863 | 0.010 |
Why?
|
| Thyrotropin | 1 | 1978 | 849 | 0.010 |
Why?
|
| Thyroxine | 1 | 1978 | 667 | 0.010 |
Why?
|
| Eye Manifestations | 1 | 1974 | 11 | 0.010 |
Why?
|
| Brachial Artery | 1 | 1976 | 369 | 0.010 |
Why?
|
| Hypothyroidism | 1 | 1978 | 658 | 0.010 |
Why?
|
| Autoimmune Diseases | 1 | 1985 | 2133 | 0.010 |
Why?
|
| Stress, Physiological | 1 | 1980 | 1403 | 0.010 |
Why?
|
| Glutamine | 1 | 1976 | 578 | 0.010 |
Why?
|
| Glycine | 1 | 1976 | 671 | 0.010 |
Why?
|
| Leukopenia | 1 | 1973 | 212 | 0.010 |
Why?
|
| Serine | 1 | 1976 | 826 | 0.010 |
Why?
|
| Rats | 2 | 1981 | 24260 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 2006 | 7785 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2006 | 11366 | 0.010 |
Why?
|
| Herpesvirus 4, Human | 1 | 1977 | 1041 | 0.010 |
Why?
|
| Veins | 1 | 1976 | 770 | 0.010 |
Why?
|
| Kinetics | 1 | 1979 | 6473 | 0.010 |
Why?
|
| Waldenstrom Macroglobulinemia | 1 | 1981 | 1052 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2012 | 25043 | 0.010 |
Why?
|
| Pleural Effusion | 1 | 1974 | 338 | 0.010 |
Why?
|
| Virus Diseases | 1 | 1977 | 711 | 0.010 |
Why?
|
| Structure-Activity Relationship | 1 | 1976 | 3129 | 0.010 |
Why?
|
| Leukemia, Myeloid | 1 | 1973 | 707 | 0.010 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 1976 | 1116 | 0.010 |
Why?
|
| Blood Platelets | 1 | 1980 | 2508 | 0.010 |
Why?
|
| Terminology as Topic | 1 | 1977 | 1547 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2006 | 15540 | 0.000 |
Why?
|
| Spectrometry, Fluorescence | 1 | 1989 | 689 | 0.000 |
Why?
|
| Dexamethasone | 1 | 1974 | 1951 | 0.000 |
Why?
|
| Postmenopause | 1 | 1995 | 2461 | 0.000 |
Why?
|
| HLA-DR4 Antigen | 1 | 1985 | 28 | 0.000 |
Why?
|
| HLA-DR3 Antigen | 1 | 1985 | 34 | 0.000 |
Why?
|
| HLA-DR2 Antigen | 1 | 1985 | 48 | 0.000 |
Why?
|
| Antibodies | 2 | 1984 | 2460 | 0.000 |
Why?
|
| Thrombocytopenia | 1 | 1973 | 1179 | 0.000 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1989 | 2505 | 0.000 |
Why?
|
| Body Mass Index | 1 | 2002 | 12720 | 0.000 |
Why?
|
| Somatostatin-28 | 1 | 1983 | 6 | 0.000 |
Why?
|
| Immunoenzyme Techniques | 1 | 1987 | 1799 | 0.000 |
Why?
|
| HLA-DR Antigens | 1 | 1985 | 645 | 0.000 |
Why?
|
| Smoking | 1 | 1980 | 8987 | 0.000 |
Why?
|
| Hyperlipoproteinemias | 1 | 1983 | 20 | 0.000 |
Why?
|
| Chromatography, Gel | 1 | 1983 | 668 | 0.000 |
Why?
|
| Multiple Myeloma | 1 | 1981 | 5181 | 0.000 |
Why?
|
| Histocompatibility Testing | 1 | 1983 | 741 | 0.000 |
Why?
|
| Cells, Cultured | 1 | 1977 | 19229 | 0.000 |
Why?
|
| Age Factors | 2 | 1992 | 18370 | 0.000 |
Why?
|
| Leukemia, Lymphoid | 1 | 1981 | 315 | 0.000 |
Why?
|
| Diet | 1 | 1978 | 7939 | 0.000 |
Why?
|
| Adipose Tissue | 1 | 1971 | 3279 | 0.000 |
Why?
|
| Phenotype | 1 | 1977 | 16365 | 0.000 |
Why?
|
| Protein Precursors | 1 | 1983 | 1154 | 0.000 |
Why?
|
| Child, Preschool | 3 | 1989 | 41006 | 0.000 |
Why?
|
| Pedigree | 1 | 1985 | 4644 | 0.000 |
Why?
|
| Disease Models, Animal | 1 | 1976 | 18029 | 0.000 |
Why?
|
| Immunoglobulin A | 1 | 1981 | 992 | 0.000 |
Why?
|
| Triiodothyronine | 1 | 1978 | 494 | 0.000 |
Why?
|
| Immunoglobulin M | 1 | 1981 | 1537 | 0.000 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 1987 | 2214 | 0.000 |
Why?
|
| Glycerol | 1 | 1975 | 278 | 0.000 |
Why?
|
| Alleles | 1 | 1985 | 6933 | 0.000 |
Why?
|
| Mice | 1 | 1981 | 81183 | 0.000 |
Why?
|
| Infant | 2 | 1989 | 35136 | 0.000 |
Why?
|
| Dietary Carbohydrates | 1 | 1978 | 906 | 0.000 |
Why?
|
| Blood Cells | 1 | 1975 | 309 | 0.000 |
Why?
|
| Dietary Proteins | 1 | 1978 | 963 | 0.000 |
Why?
|
| Lymphoma | 1 | 1981 | 1877 | 0.000 |
Why?
|
| Peptides | 1 | 1983 | 4409 | 0.000 |
Why?
|
| Liver Neoplasms | 1 | 1987 | 4253 | 0.000 |
Why?
|
| Registries | 1 | 1983 | 8089 | 0.000 |
Why?
|